Arrowhead Research | ARWR
Stock Price
18.54
Daily Change
0.26 1.42%
Monthly
-6.93%
Yearly
-36.33%
Q4 Forecast
20.32


Peers Price Chg Day Year Date
Agios Pharmaceuticals 55.68 0.14 0.25% 149.35% Nov/22
Alnylam Pharmaceuticals 244.89 -1.91 -0.77% 50.31% Nov/22
Arrowhead Research 18.54 0.26 1.42% -36.33% Nov/22
Incyte 71.72 1.33 1.89% 33.46% Nov/22
Ionis Pharmaceuticals 34.01 0.07 0.21% -31.75% Nov/22
Ligand Pharmaceuticals 119.19 2.64 2.27% 98.35% Nov/22
Merck 99.27 -0.86 -0.86% -2.55% Nov/22
Moderna 41.14 2.82 7.35% -47.61% Nov/22
Novartis 93.68 2.12 2.32% 8.61% Nov/22
Ultragenyx Pharmaceutical 47.24 1.22 2.65% 20.69% Nov/22
Sarepta Therapeutics 114.23 3.73 3.38% 37.84% Nov/22
TG Therapeutics 35.07 0.52 1.51% 174.20% Nov/22
Vertex Pharmaceuticals 451.02 0.87 0.19% 27.75% Nov/22
Xencor 25.01 0.91 3.78% 33.46% Nov/22

Indexes Price Day Year Date
USND 19004 31.23 0.16% 33.35% Nov/22
US2000 2407 42.65 1.80% 33.15% Nov/22
US400 3342 54.93 1.67% 30.52% Nov/22

Arrowhead Research traded at $18.54 this Friday November 22nd, increasing $0.26 or 1.42 percent since the previous trading session. Looking back, over the last four weeks, Arrowhead Research gained 6.93 percent. Over the last 12 months, its price fell by 36.33 percent. Looking ahead, we forecast Arrowhead Research to be priced at 20.32 by the end of this quarter and at 19.58 in one year, according to Trading Economics global macro models projections and analysts expectations.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.